45 research outputs found

    Mucormycosis: an emerging disease?

    Get PDF
    ABSTRACTMucormycosis is the third invasive mycosis in order of importance after candidiasis and aspergillosis and is caused by fungi of the class Zygomycetes. The most important species in order of frequency is Rhizopus arrhizus (oryzae). Identification of the agents responsible for mucormycosis is based on macroscopic and microscopic morphological criteria, carbohydrate assimilation and the maximum temperature compatible with its growth. The incidence of mucormycosis is approximately 1.7 cases per 1000 000 inhabitants per year, and the main risk-factors for the development of mucormycosis are ketoacidosis (diabetic or other), iatrogenic immunosuppression, use of corticosteroids or deferoxamine, disruption of mucocutaneous barriers by catheters and other devices, and exposure to bandages contaminated by these fungi. Mucorales invade deep tissues via inhalation of airborne spores, percutaneous inoculation or ingestion. They colonise a high number of patients but do not cause invasion. Mucormycosis most commonly manifests in the sinuses (39%), lungs (24%), skin (19%), brain (9%), and gastrointestinal tract (7%), in the form of disseminated disease (6%), and in other sites (6%). Clinical diagnosis of mucormycosis is difficult, and is often made at a late stage of the disease or post-mortem. Confirmation of the clinical form requires the combination of symptoms compatible with histological invasion of tissues. The probable diagnosis of mucormycosis requires the combination of various clinical data and the isolation in culture of the fungus from clinical samples. Treatment of mucormycosis requires a rapid diagnosis, correction of predisposing factors, surgical resection, debridement and appropriate antifungal therapy. Liposomal amphotericin B is the therapy of choice for this condition. Itraconazole is considered to be inappropriate and there is evidence of its failure in patients suffering from mucormycosis. Voriconazole is not active in vitro against Mucorales, and failed when used in vivo. Posaconazole and ravuconazole have good activity in vitro. The overall rate of mortality of mucormycosis is approximately 40%

    Revista de informaci贸n de la Comisi贸n Nacional Espa帽ola de Cooperaci贸n con la UNESCO

    No full text
    T铆tulo anterior de la publicaci贸n : Bolet铆n de la Comisi贸n Espa帽ola de la UNESCOInforme sobre la situaci贸n medioambiental de la isla Tunecina de Djerba, tur铆stica por excelencia, que est谩 viendo mermados su agricultura debido a la sequ铆a y a la desertificaci贸n. Se emprendi贸 un estudio como parte del Programa de la Unesco sobre el Hombre y la Biosfera con el objetivo de estudiar las posibilidades de preservar el car谩cter tradicional de la isla, sin perjudicar su desarrollo econ贸mico. Este proyecto se refer铆a a la conservaci贸n de la arquitectura tradicional y de los oficios tradicionales, viviendo en armon铆a con las instalaciones tur铆sticas. La actividad m谩s importante dentro del Programa fue instaurar entre los escolares, una educaci贸n y conciencia ambiental, una preocupaci贸n por el medio ambiente y la necesidad de proteger los recursos naturales. Se elabor贸 un material educativo utilizando carteles con dibujos explicativos, pinturas murales y manuales con textos elementales que describ铆an experimentos ecol贸gicos f谩ciles de preparar, y que pod铆an realizarse dentro y fuera de la clase. La acogida de los ni帽os de esta actividad fue muy satisfactoria.Ministerio Educaci贸n CIDEBiblioteca de Educaci贸n del Ministerio de Educaci贸n, Cultura y Deporte; Calle San Agust铆n, 5 - 3 Planta; 28014 Madrid; Tel. +34917748000; [email protected]

    Youth and society

    No full text

    Role of a FMRFamide-like family of neuropeptides in the pharyngeal nervous system of Caenorhabditis elegans

    No full text
    The nervous system of C. elegans has a remarkable abundance of flp genes encoding FMRFamide-like (FLP) neuropeptides. To provide insight into the physiological relevance of this neuropeptide diversity, we have tested more than 30 FLPs (encoded by 23 flps) for bioactivity on C. elegans pharynx. Eleven flp genes encode peptides that inhibit pharyngeal activity, while eight flp genes encode peptides that are excitatory. Three potent peptides (inhibitory, FLP-13A, APEASPFIRFamide; excitatory, FLP-17A, KSAFVRFamide; excitatory, FLP-17B, KSQYIRFamide) are encoded by flp genes, which, according to reporter gene constructs, are expressed in pharyngeal motoneurons. Thus, they may act through receptors localized on the pharyngeal muscle. The two other potent peptides, FLP-8 (excitatory AF1, KNEFIRFamide,) and FLP-11A (inhibitory, AMRNALVRFamide), appear to be expressed in extrapharyngeal neurons and are therefore likely to act either indirectly or as neurohormones. Intriguingly, a single neuron can express peptides that have potent but opposing biological activity in the pharynx. Only five flp genes encode neuropeptides that have no observable effect on the pharynx, but none of these have shown reporter gene expression in the pharyngeal nervous system. To examine the roles of multiple peptides produced from single precursors, a comparison was made between the bioactivity of different neuropeptides for five flp genes (flp-3, flp-13, flp-14, flp-17, and flp-18). For all but one gene (flp-14), the effects of peptides encoded by the same gene were similar. Overall, this study demonstrates the impressive neurochemical complexity of the simple circuit that regulates feeding in the nematode, C. elegans. 漏 2005 Wiley Periodicals, Inc. J Neurobiol, 200
    corecore